|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis显示文摘The 'a disintegrin and metalloprotease' (ADAM) family contributes to regulation of the cell-cell and cell-matrix interactions that are critical determinants of malignancy. To determine the relationship between metastasis and ADAM proteins, we compared the mRNA levels of ADAM9,-10,-12,-15, and-17 in sublines of an EBC-1 lung cancer cell line that were highly metastatic to either brain or bone. ADAM9 mRNA levels were significantly higher in highly brain-metastatic sublines than in the parent or highly bonemetastalic sublines. To elucidate the role ofADAM9 in brain metastasis, we stably transfected A549 and EBC-1 cells with a fulllength ADAM9 expression vector. Compared with mock-transfectants, ADAM9 overexpression resulted in increased invasive capacity | Shintani Y Higashiyama S Ohta M Hirabayashi H Yamamoto S Yoshimasu T Matsuda H Matsuura N | 2004 | 中国神经肿瘤杂志2004，2，2： | 36 |
| 2 | 一种房颤风险评分系统的建立(Framingham心脏研究):基于社区的队列研究显示文摘背景房颤导致了发病率和病死率的显著上升。本研究旨在建立一种预测个体罹患房颤绝对风险的风险评分系统,并提供研究人员评价新危险因素的流程。方法作者评估了Framingham心脏研究中于1968年6月至1987年9月间进行了8044次检测的4764例参与者(55%为女性,年龄45~95岁)。此后,参与者被随访至房颤首发,随访期最长达10年。多变量Coxi回归确认出1(1年内罹患房颤的临床危险因素。次级分析纳入了常规超声心动图检测指标(5152例4参与者,7156次检测)对房颤风险进行再分层评估,并评价超声检测指标能否提高风险预测能力。结果4764例参与者中的457例4(10%)罹患房颤。年龄、性别、体重指数、收缩压、降压治疗、PR间期、有临床意义的心脏杂音及心力衰竭与房颤相关,并被纳入了风险评分模型(除体重指数P=0.08外,其余均为P〈0.05),模型的C统计量为0.78(95%CI0.76~0.80)。10年房颤风险随年龄变化:年龄〈65岁的人群中53例(1%)风险高于15%,而〉65岁的人群中为783例(27%)。为提高预测能力而纳入超声检测指标仅使模型C统计量略微增高,由0.78(95%C10.75~0.80)增至0.79(95%CI0.77~0.82:P=0.005)。超声心动图检测指标并不能改善风险再分层评估(P=0.18)。结论基于社区医疗中易得的临床因素建立的风险评分系统,有助于确认社区个体罹患房颤的风险,评估技术或标志物能否改善风险预测,以及针对高危个体采取预防措施。 | Renate B Schnabel Lisa M Sullivan Daniel Levy Michael J Pencina Joseph M Massaro Ralph B D'Agostino Sr Christopher Newton-Cheh Jennifer F Yamamoto Jared W Magnani Thomas M Tadros William B Kannel Thomas J Wang Patrick T Ellinor Philip A Wolf Ramachanclran S Vasan Emelia J Benjamin 黄刚(译) | 2009 | 世界临床医学2009，，9： | 2 |
| 3 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomised phase 3 study显示文摘 | Boku N Yamamoto S Fukuda H | | 0，，11： | 2 |
| 4 | A Minimax Rule forPortfolio Selection in Frictional Markets显示文摘 | Wang S Y Yamamoto Y Yu M | 2003 | Mathematical Methods of Operations Research2003，57，： | 2 |
| 5 | Chemical analysis of surfaces by total-reflection-angle X-ray spectroscopy in rheed experiments (rheed-traxs)显示文摘 | HASEGAWA S YAMAMOTO 1 Y DAIMON H | 1985 | Jpn J Appl Phys1985，24，6： | 2 |
| 6 | Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity显示文摘 | Yamamoto S Yamamoto T Kataoka T | 1992 | J Immunol1992，148，： | 2 |
| 7 | 胆固醇酯转移蛋白基因的蛋白质截断型变异体与冠状动脉性心脏病风险的关系显示文摘随机对照试验结果表明,抑制胆固醇酯转运蛋白(cholesteryl ester transfer protein,CETP)的疗法并不能降低冠状动脉性心脏病(coronary heart disease,CHD)的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应和随机对照设计因素影响等。在编码药物靶点的基因中具有天然存在的遗传变异,以此为基础,人类研究可以深入了解针对基因产物的治疗的潜在功效和安全性。 | Nomura A Won HH Khera AV Takeuchi F Ito K McCarthy S Emdin CA Klarin D Natarajan P Zekavat SM Gupta N Peloso GM Borecki IB Teslovich TM Asselta R Duga S Merlini PA Correa A Kessler T Wilson JG Bown MJ Hall AS Braund PS Carey DJ Murray MF Kirchner HL Leader JB Lavage DR Manus JN Hartze DN Samani NJ Schunkert H Marrugat J Elosua R McPherson R Farrall M Watkins H Juang JJ Hsiung CA Lin SY Wang JS Tada H Kawashiri MA Inazu A Yamagishi M Katsuya T Nakashima E Nakatochi M Yamamoto K Yokota M Momozawa Y Rotter JI Lander ES Rader DJ Danesh J Ardissino D Gabriel S Willer CJ Abecasis GR Saleheen D Kubo M Kato N Ida Chen YD Dewey FE Kathiresan S 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，9： | 2 |
| 8 | 初产妇和经产妇妊娠期间的诊室和家庭血压显示文摘妊娠高血压可导致分娩时产生严重的并发症,如脑卒中、早产或低出生体质量。初产妇被认为是妊娠高血压的一个危险因素。产次与妊娠期间家庭血压相关性仍不明确。方法:入选初产妇和经产妇共575名,评估妊娠高血压和先兆子痫的发病率。收集在一家日本产科医院接受产前检查的530名正常血压孕妇的家庭和诊室血压值。诊室血压为产前检查2次测量的血压平均值,参与者妊娠期间每日清晨在家自测血压。 | Ishikuro M Obara T Metoki H Ohkubo T Yamamoto M Akutsu K Sakurai K Iwama N Katagiri M Yagihashi K Yaegashi N Mori S Suzuki M Kuriyama S Imai Y 罗冬梅 叶鹏 | 2013 | 中华高血压杂志2013，21，6： | 2 |
| 9 | Protective effect of Irsogladine on monochloramineinduced gastric mucosallesions in rats:a comparative study with rebamipide显示文摘AIM To examine the effect of irsogladine, a novel antiulcer drug, on the mucosal ulcerogenic response to monochloramine (NH 2Cl) in rat stomach, in comparison with rebamipide, another antiulcer drug with cytoprotective activity. METHODS AND RESULTS Oral administration of NH 2Cl (120*!mM) produced severe hemorrhagic lesions in unanesthetized rat stomachs. Both irsogladine ( 1*!mg/*!kg - 10*!mg/*!kg , po ) and rebamipide ( 30*!mg/*!kg - 100*!mg/*!kg , po ) dose dependently prevented the development of these lesions in response to NH 2Cl, the effect of irsogladine was significant at 3*!mg/*!kg or greater, and that of rebamipide only at 100*!mg/*!kg . The protective effect of irsogladine on NH 2Cl induced gastric lesions was significantly reduced by N G nitro L arginine methyl ester (L NAME) but not by indomethacin, while that of rebamipide was significantly mitigated by indomethacin but not by L NAME. Topical application of NH 2Cl (20*!mM) caused a marked reduction of potential difference (PD) in ex vivo stomachs. This PD reduction was not affected by mucosal application of irsogladine, but significantly prevented by rebamipide. The mucosal exposure to NH 4OH (120*!mM) also caused a marked PD reduction in the ischemic stomach (bleeding from the carotid artery), resulting in gastric lesions. These ulcerogenic and PD responses caused by NH 4OH plus ischemia were also significantly mitigated by rebamipide, in an indomethacin sensitive manner, while irsogladine potently prevented such lesions without affecting the PD response, in a L NAME sensitive manner. CONCLUSION These results suggest that ① NH 2Cl generated either exogenously or endogenously damages the gastric mucosa, ② both irsogladine and rebamipide protect the stomach against injury caused by NH 2Cl, and ③ the mechanism underlying the protective action of irsogladine is partly mediated by endogenous nitric oxide, while that of rebamipide is in part mediated by endogenous prostaglandins. | H Yamamoto, M Umeda, H Mizoguchi, S Kato and K Takeuchi | 1999 | World Journal of Gastroenterology1999，5，6： | 2 |
| 10 | Temperature-dependent distribution of internal magnetic fields at 57Fe nuclei in FCC iron-nickel alloys显示文摘 | Tomiyoshi S Yamamoto H Watanabe H | 1971 | J Phys Soc JPN1971，30，： | 2 |
| 11 | Antioxidative properties of Jaffa sweeties and grapefruit and their influence on lipid metabolism and plasma antioxidative potential in rats显示文摘 | Gorinstein S Yamamoto K Katrich E | 2003 | Biosci Biotechnol Biochem2003，67，： | 1 |
| 12 | 3-D Thermodynamic Analysis of Superhydrophobic Surfaces 显示文摘 | Yamamoto K Ogata S | 2008 | J Colloid Interface Sci2008，326，2： | 1 |
| 13 | Expression of vascular endothelial growth factor in human gastric carcinomas显示文摘 | Yasui W Kitadai Y | 1998 | Pathol Int1998，48，7： | 1 |
| 14 | 显示文摘 | Baba N Tajima S | 1981 | Nature1981，289，： | 1 |
| 15 | Concentrations of vascular endothelial growth factor in sera of normal contrals and cancer patients显示文摘 | Toi M Kondo S | 1996 | Clin Cancer Res1996，2，： | 1 |
| 16 | Predisposing factors to enlargement of spontaneous intracerebral hematomas显示文摘 | Minematsu K Yamamoto H | 1997 | Stroke1997，28，： | 1 |
| 17 | The prognostic value of both neuron-specific-enolase (NSE) and Cyfra21-1 in small cell lung cancer显示文摘 | ANDO S SUZUKI M YAMAMOTO N | 2004 | Anticacer Res2004，24，3： | 1 |
| 18 | J Power Sources显示文摘 | Matsuoka O Hiwara A Omi T Toriida M Hayashi T Tanaka C Saito Y Ishida T Tan H Ono S S Yamamoto S | 2002 | 108:1282002，108，： | 1 |
| 19 | Paroxysmal itching and magnetic resonance imaging of the spinal cord in multiple sclerosis 显示文摘 | Yamamoto K Kawazawa S Takase Y | 1989 | Rinsho Shinkeigaku1989，29，11： | 1 |
| 20 | Overexpression of polo-like kinase1(PLK1) and chromosomal instability in bladder cancer显示文摘 | Yamamoto Y Matsuyama H Kawauchi S | 2006 | Oncology2006，70，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员